Disruption of protein kinase A regulation causes immortalization and dysregulation of D-type cyclins

被引:55
作者
Nadella, KS
Kirschner, LS
机构
[1] Ohio State Univ, Dept Med, Human Canc Genet Program, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Internal Med, Div Endocrinol Diabet & Metab, Columbus, OH 43210 USA
关键词
D O I
10.1158/0008-5472.CAN-05-3183
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphorylation is a key event in cell cycle control, and dysregulation of this process is observed in many tumors, including those associated with specific inherited neoplasia syndromes. We have shown previously that patients with the autosomal dominant tumor predisposition Carney complex carry inactivating mutations in the PRKAR1A gene, which encodes the type 1A regulatory subunit of protein kinase A (PKA), the cyclic AMP-dependent protein kinase. This defect was associated with dysregulation of PKA signaling, and genetic analysis has suggested that complete loss of the gene may be required for tumorigenesis. To determine the mechanism by which dysregulation of PKA causes tumor formation, we generated in vitro primary mouse cells lacking the Prkar1a protein. We report that this genetic disruption of PKA regulation causes constitutive PKA activation and immortalization of primary mouse embryonic fibroblasts (MEFs). At the molecular level, knockout of Prkar1a leads to up-regulation of D-type cyclins, and this increase occurs independently of other pathways known to increase cyclin D levels. Despite the immortalized phenotype, known mediators of cellular senescence (e.g., p53 and p19(ARF)) seem to remain intact in Prkar1a(-/-) MEFs. Mechanistically, cyclin D1 mRNA levels are not altered in the knockout cells, but protein half-life is markedly increased. Using this model, we provide the first direct genetic evidence that dysregulation of PKA promotes important steps in tumorigenesis, and that cyclin D1 is an essential target of PKA.
引用
收藏
页码:10307 / 10315
页数:9
相关论文
共 50 条
  • [1] Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter
    Agarwal, SK
    Novotny, EA
    Crabtree, JS
    Weitzman, JB
    Yaniv, M
    Burns, AL
    Chandrasekharappa, SC
    Collins, FS
    Spiegel, AM
    Marx, SJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (19) : 10770 - 10775
  • [2] Increased basal cAMP-dependent protein kinase activity inhibits the formation of mesoderm-derived structures in the developing mouse embryo
    Amieux, PS
    Howe, DG
    Knickerbocker, H
    Lee, DC
    Su, T
    Laszlo, GS
    Idzerda, RL
    McKnight, GS
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (30) : 27294 - 27304
  • [3] p27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes
    Bagui, TK
    Mohapatra, S
    Haura, E
    Pledger, WJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (20) : 7285 - 7290
  • [4] Analysis of cyclin D3-cdk4 complexes in fibroblasts expressing and lacking p27kip1 and p21cip1
    Bagui, TK
    Jackson, RJ
    Agrawal, D
    Pledger, WJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (23) : 8748 - 8757
  • [5] Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation
    Bardeesy, N
    Sinha, M
    Hezel, AF
    Signoretti, S
    Hathaway, NA
    Sharpless, NE
    Loda, M
    Carrasco, DR
    DePinho, RA
    [J]. NATURE, 2002, 419 (6903) : 162 - 167
  • [6] Bertherat J, 2003, CANCER RES, V63, P5308
  • [7] Guidelines for diagnosis and therapy of MEN type 1 and type 2
    Brandi, ML
    Gagel, RF
    Angeli, A
    Bilezikian, JP
    Beck-Peccoz, P
    Bordi, C
    Conte-Devolx, B
    Falchetti, A
    Gheri, RG
    Libroia, A
    Lips, CJM
    Lombardi, G
    Mannelli, M
    Pacini, F
    Pondder, BAJ
    Raue, F
    Skogseid, B
    Tamburrano, G
    Thakker, RV
    Thompson, NW
    Tomassetti, P
    Tonelli, F
    Wells, SA
    Marx, SJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) : 5658 - 5671
  • [8] The role of p27Kip1 in maintaining the levels of D-type cyclins in vivo
    Bryja, V
    Pacherník, J
    Faldíková, L
    Krejcí, P
    Pogue, R
    Nevrivá, I
    Dvorák, P
    Hampl, A
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2004, 1691 (2-3): : 105 - 116
  • [9] Tumor suppressor p16INK4A:: Determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4
    Byeon, IJL
    Li, JN
    Ericson, K
    Selby, TL
    Tevelev, A
    Kim, HJ
    O'Maille, P
    Tsai, MD
    [J]. MOLECULAR CELL, 1998, 1 (03) : 421 - 431
  • [10] THE COMPLEX OF MYXOMAS, SPOTTY PIGMENTATION, AND ENDOCRINE OVERACTIVITY
    CARNEY, JA
    GORDON, H
    CARPENTER, PC
    SHENOY, BV
    GO, VLW
    [J]. MEDICINE, 1985, 64 (04) : 270 - 283